Karyopharm Therapeutics Inc. reiterated revenue guidance for the full year 2023. For the year, the company expected total revenue to be in the range of $145 million to $160 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.095 USD | +3.30% | -3.54% | +26.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.01% | 123M | |
-2.93% | 103B | |
+1.36% | 95.28B | |
+1.46% | 22.15B | |
-16.05% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.25% | 16.05B | |
+4.87% | 13.68B | |
+33.03% | 12.17B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023